Mupadolimab (CPI-006) is an IgG1κ humanized FcγR binding-deficient anti-CD73 monoclonal antibody (mAb) that activates CD73POS B cells[1].
Mupadolimab induces the increased expression of markers associated with B cell maturation and antigen presentation, morphologic transformation to plasmablasts, and increased secretion of IgM and IgG[1].
Mupadolimab (10 mg/kg; i.p.; daily for 15 days) stimulates antigen specific humoral immunity in SARS-CoV-2 infected NSG-SGM3 mice[1].
| Animal Model: | NSG-SGM3 mice, immunized with an emulsion of 50 μg full length spike protein from SARS-CoV-2 and Freund's Incomplete Adjuvant subcutaneously on both the left and right flank (25 μg/side)[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection, daily for 15 days |
| Result: | Mice treated with the drug made antibodies to the immunizing TS protein; but not to the control nucleocapsid SARS-CoV-2 viral protein. |
[1]. Miller R A, et al. Clinical results with a B cell activating anti-CD73 antibody for the immunotherapy of Covid-19. medRxiv, 2021.